MX2009006077A - Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. - Google Patents

Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.

Info

Publication number
MX2009006077A
MX2009006077A MX2009006077A MX2009006077A MX2009006077A MX 2009006077 A MX2009006077 A MX 2009006077A MX 2009006077 A MX2009006077 A MX 2009006077A MX 2009006077 A MX2009006077 A MX 2009006077A MX 2009006077 A MX2009006077 A MX 2009006077A
Authority
MX
Mexico
Prior art keywords
disorders
pharmaceutically acceptable
compounds
arylsulfonyl
heterocyclyl
Prior art date
Application number
MX2009006077A
Other languages
English (en)
Inventor
Nirogi Venkata Satya Ramakrishna
Rama Sastri Kambhampati
Prabhakar Kothmirkar
Venkateswarlu Jasti
Jagadishbabu Konda
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2009006077A publication Critical patent/MX2009006077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome

Abstract

La presente invención se relaciona con compuestos novedosos de 5-(heterociclil)alquil-N-(arilsulfonil)indol de la fórmula (I), sus derivados, sus estereoisómeros, sus sales farmacéuticamente aceptables y las composiciones farmacéuticamente aceptables que los contienen. La presente invención también se relaciona con un proceso para la preparación de los compuestos novedosos anteriores, sus derivados, sus estereoisómeros, sus sales farmacéuticamente aceptables y las composiciones farmacéuticamente aceptables que los contienen. Estos compuestos son útiles en el tratamiento de varios trastornos que están relacionados con las funciones del receptor de 5-HT6. De manera específica, los compuestos de esta invención también son útiles en el tratamiento de varios trastornos del CNS, trastornos hematológicos, trastornos de la alimentación, enfermedades asociadas con el dolor, enfermedades respiratorias, trastornos genitourológicos, enfermedades cardiovasculares y cáncer.
MX2009006077A 2007-01-08 2007-07-26 Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. MX2009006077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN45CH2007 2007-01-08
PCT/IN2007/000312 WO2008084492A1 (en) 2007-01-08 2007-07-26 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands

Publications (1)

Publication Number Publication Date
MX2009006077A true MX2009006077A (es) 2009-06-17

Family

ID=39495814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006077A MX2009006077A (es) 2007-01-08 2007-07-26 Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.

Country Status (23)

Country Link
US (1) US8470830B2 (es)
EP (1) EP2114878B1 (es)
JP (1) JP2010515674A (es)
KR (1) KR101103023B1 (es)
CN (1) CN101553467B (es)
AT (1) ATE491685T1 (es)
AU (1) AU2007343063B2 (es)
BR (1) BRPI0718737A2 (es)
CA (1) CA2670717C (es)
CY (1) CY1111105T1 (es)
DE (1) DE602007011323D1 (es)
DK (1) DK2114878T3 (es)
EA (1) EA017007B1 (es)
ES (1) ES2357584T3 (es)
HK (1) HK1132273A1 (es)
IL (1) IL198821A (es)
MX (1) MX2009006077A (es)
NO (1) NO341713B1 (es)
NZ (1) NZ577769A (es)
PL (1) PL2114878T3 (es)
PT (1) PT2114878E (es)
WO (1) WO2008084492A1 (es)
ZA (1) ZA200903600B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
KR20160089409A (ko) * 2013-11-25 2016-07-27 노보겐 리미티드 항암제로서 기능화되고 치환된 인돌
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
CA2953004C (en) * 2014-07-08 2023-02-21 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
SG11201610195UA (en) * 2014-07-16 2017-01-27 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
CA3182412A1 (en) * 2020-07-06 2022-01-13 Mathew BAGGOTT Advantageous benzothiophene compositions for mental disorders or enhancement

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
WO1999002502A2 (en) 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE69937372T2 (de) 1999-04-21 2008-06-26 Nps Allelix Corp., Mississauga Piperidin-indol derivate mit 5-ht6 affinität
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
EA006205B1 (ru) * 2000-11-02 2005-10-27 Уайт 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
CN1275967C (zh) 2001-01-30 2006-09-20 伊莱利利公司 用作5－ht6受体拮抗剂的苯磺酸吲哚－5－基酯
WO2002098878A1 (en) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
JP4187642B2 (ja) 2001-06-07 2008-11-26 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６受容体親和性を有する新規インドール誘導体
EP1414442A1 (en) * 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2005528587A (ja) 2002-02-01 2005-09-22 バイエル・ヘルスケア・アクチェンゲゼルシャフト 新規ヒト５−ｈｔ６受容体に関連する疾患のための診断用および治療用物質
JP2005522432A (ja) 2002-02-05 2005-07-28 グラクソ　グループ　リミテッド ニューロン成長の促進方法
PL209872B1 (pl) 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
KR100818508B1 (ko) 2002-11-28 2008-03-31 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 엔-아릴술포닐-3-치환인돌, 그 제조방법 및 그를 포함하는 약제학적 조성물
ES2425143T3 (es) 2002-11-28 2013-10-11 Suven Life Sciences Limited N-Arilsulfonil-3-aminoalcoxiindoles
KR100739987B1 (ko) 2002-12-18 2007-07-16 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 테트라사이클릭 3-치환인돌
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
ES2222828B1 (es) * 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
DK1919896T3 (da) 2005-08-12 2010-04-19 Suven Life Sciences Ltd Aminoarylsulfonamidderivater, som funktionelle 5-HT6-ligander
ES2398299T3 (es) * 2006-07-03 2013-03-15 Proximagen Ltd. Indoles como moduladores de 5-HT6

Also Published As

Publication number Publication date
US8470830B2 (en) 2013-06-25
CN101553467B (zh) 2011-12-07
EP2114878A1 (en) 2009-11-11
HK1132273A1 (es) 2010-02-19
US20100041673A1 (en) 2010-02-18
KR101103023B1 (ko) 2012-01-05
AU2007343063A1 (en) 2008-07-17
KR20090080544A (ko) 2009-07-24
EA200970675A1 (ru) 2009-12-30
IL198821A (en) 2014-11-30
EP2114878B1 (en) 2010-12-15
CY1111105T1 (el) 2015-06-11
NO20092067L (no) 2009-09-04
ATE491685T1 (de) 2011-01-15
NO341713B1 (no) 2018-01-08
ES2357584T3 (es) 2011-04-27
ZA200903600B (en) 2010-07-28
IL198821A0 (en) 2010-02-17
BRPI0718737A2 (pt) 2014-03-25
JP2010515674A (ja) 2010-05-13
DE602007011323D1 (de) 2011-01-27
PT2114878E (pt) 2011-03-10
CN101553467A (zh) 2009-10-07
AU2007343063B2 (en) 2011-02-17
NZ577769A (en) 2011-01-28
PL2114878T3 (pl) 2011-05-31
DK2114878T3 (da) 2011-03-14
AU2007343063A8 (en) 2009-07-23
CA2670717C (en) 2012-01-10
EA017007B1 (ru) 2012-09-28
CA2670717A1 (en) 2008-07-17
WO2008084492A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
MX2009006077A (es) Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
HK1138264A1 (en) Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
MX2010012189A (es) Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
UA88910C2 (ru) Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения
HRP20110780T1 (en) Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention
NZ601284A (en) Sulfone compounds as 5-ht6 receptor ligands
MX354852B (es) Compuestos de heterociclilo comoligandos del receptor h3 de la histamina.
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.

Legal Events

Date Code Title Description
FG Grant or registration